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ABSTRACT
Palliative care in acute myeloid leukaemia (AML) is inadequate. For elderly 
patients, unfit for intensive chemotherapy, median survival is 2–3 months. As such, 
there is urgent demand for low-toxic palliative alternatives. We have repositioned two 
commonly administered anti-leukaemia drugs, valproic acid (VPA) and hydroxyurea 
(HU), as a combination therapy in AML.
The anti-leukemic effect of VPA and HU was assessed in multiple AML cell lines 
confirming the superior anti-leukemic effect of combination therapy. Mechanistic 
studies revealed that VPA amplified the ability of HU to slow S-phase progression 
and this correlated with significantly increased DNA damage. VPA was also shown 
to reduce expression of the DNA repair protein, Rad51. Interestingly, the tumour 
suppressor protein p53 was revealed to mitigate cell cycle recovery following 
combination induced arrest. The efficacy of combination therapy was validated in vivo. 
Combination treatment increased survival in OCI-AML3 and patient-derived xenograft 
mouse models of AML. Therapy response was confirmed by optical imaging with 
multiplexed near-infrared labelled antibodies.
The combination of HU and VPA indicates significant potential in preclinical 
models of AML. Both compounds are widely available and well tolerated. We believe 
that repositioning this combination could significantly enhance the palliative care of 
patients unsuited to intensive chemotherapy. 
INTRODUCTION
Palliative care in acute myeloid leukaemia (AML) 
is unsatisfactory. For elderly patients, who do not tolerate 
intensive chemotherapy or bone marrow transplantation, 
median survival is 2–3 months [1, 2]. AML is a genetically 
heterogeneous disease and numerous classes of anticancer 
agents have been trialled with varying success. Histone 
deacetylase inhibitors (HDACi) have indicated significant 
potential, whilst DNA targeting compounds remain a 
stalwart of clinical practice [3]. Emerging studies continue 
to reveal novel molecular mechanisms underpinning these 
agents. Such molecular insights also provide a unique 
opportunity to reassess existing therapeutics. 
Valproic acid (VPA) is a short chain fatty acid used 
clinically as an anticonvulsant for more than 30 years. In 
2001 the compound was rediscovered for its anticancer 
activity as an HDAC inhibitor, (HDACi) targeting class 
1 and 2 HDAC enzymes [4]. A multitude of preclinical 
studies have combined VPA with genotoxic and non-
genotoxic therapies reporting substantially increased 
efficacy [5–8]. More recently it has been illustrated that 
this increased efficacy may be accountable to VPA’s 
capacity to modulate DNA damage repair proteins. 
Specifically VPA has been shown to target homologous 
recombination proteins, negatively regulating expression 
and localization of Rad51, Chk1, BRCA1 and BRCA2.
[9] In the last decade various clinical trials have exhibited 
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VPA’s capacity to incite clinical response in primary and 
secondary AML patients [10–13]. However, the use of 
VPA in AML is predicated on its HDACi activity and 
consequent induction of differentiation and apoptosis. 
Limited clinical emphasis has been placed on its ability to 
modulate DNA repair.
Hydroxyurea (HU) is an antimetabolite that 
targets cancer cells through stalling and subsequent 
collapse of S-phase replication forks [14]. HU inhibits 
ribonucelotide reductase thereby depleting the cellular 
pool of deoxynucleotides and incurring reversible DNA 
damage [15]. S-phase specific genomic assaults then 
depend on homologous recombination proteins, including 
Rad51, for repair [16]. The clinical importance of HU in 
myeloid neoplasms cannot be understated. Hydroxyurea 
is routinely administered to achieve leukocytoreduction in 
AML, chronic myeloid leukaemia, hyperleukocytosis and 
leukostasis [17, 18]. The safety of the compound is further 
exemplified by its on-going use and reccomendation for 
the treatment of young patients suffering from sickle cell 
anaemia [19]. In AML the compound may be prescribed 
prior to induction chemotherapy or experimentally in 
combination with other moderate or low toxic therapies, 
particularly in palliative care [20, 21]. 
Various preclinical studies have examined the 
synergistic effects of combining genotoxic compounds and 
HDACi [22–25]. However, the mechanisms described to 
account for the observed synergism remain inconclusive 
and may differ substantially depending on the models 
explored. Based on our preclinical and clinical experience 
with VPA we are appreciating its relevance in palliative 
care of AML [5, 26, 27]. Furthermore non-systematic 
testing of VPA and HU in single patients suggests the 
combination is well tolerated in elderly patients [21]. 
These factors encouraged us to reassess HU and VPA as 
a combination in preclinical models of AML. Here we 
provide evidence that HU and VPA combine effectively 
in AML through cooperative modulation of the cell cycle 
and DNA repair proteins. Additionally we identify intact 
tumour suppressor protein p53 as a likely predictor of 
therapeutic response to the combination. In vivo imaging 
and survival analysis in orthotopic mouse models, 
including a patient-derived xenograft model, confirmed 
that this combination treatment improves survival. The 
established tolerance and low toxicity of these compounds 
additionally highlights their potential in the palliative care 
of elderly AML patients. 
RESULTS
HU and VPA cooperatively induce cell death in 
p53 wild-type leukaemia cell lines
The cell death capacity of HU and VPA alone and 
in combination was assessed in four AML cell lines 
(MV4– 11, OCI-AML3, MOLM-13, and HL-60) using 
Hoechst 33342 nuclear staining. Cells were treated 
at a fixed ratio alone or in combination for 72 hours 
with increasing doses of HU (25–200 µM) and VPA 
(0.25–2 mM) (Figure 1A– 1D). Combination treatment 
consistently enhanced cell death induction as compared 
to the single agents in all cell lines. However, when 
comparing the cell viability at doses (HU 50 µM and 
VPA 0.5 mM) best reflecting patient serum concentrations 
[10, 21], the p53 null HL-60 cells were identified as the 
most resistant cell line (Figures 1A–1D). To examine 
whether p53 status can mediate therapy sensitivity 
at clinically relevant doses, 3 additional leukemic 
cell lines (KG1-A, THP-1 and K562) harbouring p53 
mutations were assessed and compared to the cell lines 
previously described. All cell lines were exposed to HU 
60 µM and VPA 0.6 mM for 72 hours to reflect clinically 
achievable concentrations [10]. Cell death in response 
to combination therapy was significantly increased in 
wild-type p53 cell lines compared to null or mutated p53 
cell lines. Comparatively, single agent therapy failed to 
distinguish significantly between cell lines with varying 
p53 status (Figures 1E–1G). To further investigate the 
significance of p53 status in response to HU and VPA 
combination therapy, we employed MOLM-13 cells 
expressing shRNA targeting p53 gene expression. 
Western blotting confirmed reduced expression of the p53 
protein in MOLM-13 shp53 cells when compared with 
MOLM- 13 wt p53 cells transduced with an untargeted 
empty vector (Figure 2A) The two cell lines were treated 
with HU (75 µM and 100 µM), VPA (0.75 mM and 
1 mM) or the combinations. Cell death was determined 
by flow cytometry using Annexin-PI staining following 
72 hrs treatment (Figure 2B–2C). At both concentration 
ratios, the combination therapy induced significantly 
more death in MOLM-13 wt p53 cells when compared 
with MOLM- 13 shp53 cells. It is a growing concern 
that chemotherapy may select for a minority of p53 
mutant clones in AML patients [28]. This may contribute 
significantly to the emergence of therapy resistant 
relapse disease. To investigate the enduring effect of the 
combination therapy, cells were exposed to HU (100 µM), 
VPA (1 mM) and the combination for 72 hrs. Cells were 
then washed twice and reseeded in drug free medium and 
maintained for a further 72 hrs. Viable cells were counted 
at 24 hr intervals throughout the course of the experiment 
(6 days). This recovery assay was performed in MOLM-
13 shp53, MOLM-13 wt p53 (Figure 2D–2G), HL-60 
(p53null) and OCI-AML3 (p53wild-type) cells (Figures H-K). 
In all cell lines untreated control cells displayed typical 
growth curves over the 6 day period, whilst VPA exerted 
a mild slowing of division rate that was lost with removal 
of the treatment. HU exhibited a more profound arrest 
in cell division, particularly in cells with wild-type p53 
status. However, again all cell lines were able to recover 
upon removal of the treatment. Uniquely, the combination 
therapy limited recovery to the HL-60 and MOLM-13 
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shp53 cell lines, with treatment resulting in a terminal 
arrest of MOLM-13 wtp53 and OCI-AML3 cells. The 
presence of substantial p53 expression therefore appears 
crucial to induction of a lasting anti-leukemic effect with 
this combination. 
HU and VPA cooperatively regulate cell cycle in 
OCI-AML3
Given the apparent significance of the role of p53 
in combination treatment response, OCI-AML3 (p53 
Figure 1: Assessment of cell death induction and the enhanced potential of combining HU and VPA in AML cell lines. 
(A-D) Hoechst nuclear staining assay performed to generate dose response curves for cell death induction. HL-60, MOLM-13, OCI-AML3 
and MV4-11 cells were treated with HU (25–200 µM) and VPA (0.25–2 mM) alone or in combination at a fixed ratio (1:10) for 72 hrs. 
N = 3. (E-G) Hoechst nuclear staining assay is performed to determine the % of viable cells in MOLM-13, OCI-AML3, MV4-11 (p53 
wild-type), KG1-A, THP-1, K562 (p53 mutated) and HL-60 cell lines. All cell lines were treated with HU (60 µM), VPA (0.6 mM) and 
the combination. Results are pooled and presented as mutated/null p53 (Mut/null p53) vs. wild-type p53 cell lines (WT p53). A significant 
increase in sensitivity was observed in WT p53 cell lines under combination treatment (**P < 0.01) N = 3.
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wild- type) cells were selected for mechanism of action 
studies. Previous studies have determined that the 
combination of HU and VPA can cooperatively arrest cell 
cycle progression resulting in enhanced cell death [23]. We 
assessed the cell cycle status of OCI-AML3 cells following 
24 hrs exposure to HU (100 µM) and VPA (1 mM), both 
alone and in combination (Figure 3A). HU slowed cell 
cycle progression with OCI-AML3 cells accumulating in 
S and G2/M phase. VPA´s capacity to induce G1 arrest is 
previously described [29], however OCI-AML3 cells were 
only mildly arrested following VPA exposure for 24 hrs 
(Control 51.7% vs. VPA 53.8%). Combination therapy 
resulted in strong S-phase arrest where the presence of 
VPA appears to amplify HU’s capacity to slow S-phase to 
G2 progression. Figure 3B illustrates that the percentage 
of cells located in S-phase at 24 hrs combination therapy 
is consistent with the fraction of cells determined to 
be necrotic (sub G1) following 72 hrs drug exposure. 
It is previously described that HU mitigates HDACi 
induction of the cyclin-dependent kinase inhibitor p21 
protein enabling cooperative initiation of S-phase driven 
apoptosis in cancer cells [23]. This trend was observed in 
the OCI- AML3 cells (Figure 3C). The capacity of VPA to 
induce p21 and simultaneously arrest cells in G1 increases 
significantly over time. To assess whether VPA had the 
capacity to protect cells from HU driven apoptosis, cells 
were pretreated with HU (100 µM) or VPA (1 mM) for 
24 hrs prior to addition of the second complementary 
compound for a further 48 hrs. Cell viability was assessed 
by Annexin-PI flow cytometry. Strikingly, when pretreated 
Figure 2: Investigating the role of p53 in HU and VPA combination therapy. (A) Lysate was produced from untreated MOLM-
13 wt and shp53 cells. Immunoblotting was performed with antibodies targeting p53 and actin. N = 3. (B) + (C) MOLM-13 wt and shp53 
cells were treated with HU (75 µM and 100 µM), VPA (0.75 mM and 1 mM) and the combination of both for 72 hrs and apoptosis was 
determined by Annexin-PI to generate dose response curves. Induction of apoptosis was compared between each cell line at particular 
treatment conditions (*P < 0.05, **P < 0.01). N = 3. (D–G) MOLM-13 wt and shp53 cells and (H-K) HL-60 and OCI-AML3 cells were 
treated with HU (100 µM) and VPA (1 mM), the combination or seeded without treatment. Following 72 hrs cells were washed 2 x in sterile 
saline and reseeded in wells. The cells were followed for a further 3 days and the number of viable cells was determined at 24 hrs intervals 
throughout the entire experimental course. Cell counts were performed using the Countess™ Automated Cell Counter (Invitrogen). N = 3.
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with VPA for 24 hrs cells were significantly more 
resistant as compared to HU pretreatment (Figure 3D). 
These results suggest that unmitigated entry to S-phase 
is necessary for synergistic induction of cell death. The 
indication that S-phase arrest is important to establish the 
synergistic effect of combination therapy is emphasized 
when cell cycle status of OCI-AML3 cells is followed 
over 72 hrs of combination treatment (Figure 3D).
HU and VPA in combination target DNA damage 
repair proteins mitigating recovery from DNA 
double strand breaks
To determine whether S-phase arrest was associated 
with anticipated HU driven DNA double strand breaks 
(DSBs), we evaluated the expression of various DNA 
damage repair proteins following exposure to both 
compounds and in combination. Protein expression was 
evaluated at 24 or 48 hrs to ensure > 65% of cells were 
viable. Immunoblotting revealed a marked increase 
in the DNA DSB indicator protein γH2AX following 
combination treatment as compared to monotherapies 
at both 24 and 48 hrs (Figure 4A). Flow cytometry 
verified these results and demonstrated additionally that 
the increased γH2AX was due to the phosphorylated 
version of the H2AX protein (Figure 4B). Interestingly 
the tumour suppressor protein p53 was unresponsive 
to HU treatment alone, but as expected expression was 
significantly increased upon VPA treatment and this was 
sustained in combination therapy. Chk1 was decreased in 
VPA monotherapy [9, 30], however expression appeared 
unaffected in the combinatory treatment, likely due to the 
increased presence of DSBs. Crucially, the homologous 
recombination repair protein, Rad51 was reduced in the 
presence of VPA, both alone and in combination with 
HU. Furthermore, immunofluorescence staining revealed 
γH2AX foci formation in the nucleus of cells exposed to 
HU or combination (Figure 4C). Additional localisation 
studies verified the formation of the DNA damage 
repair foci by nuclear imaging of the MRN complex 
member, Nsb-1, in HU and combination treated cells 
(Supplementary Figure 1A). Immunofluorescence staining 
for Rad51 indicated the protein is reduced and restricted 
to the cytoplasm in VPA treated cells (Figure 4D). The 
cytoplasmic restriction of Rad51 following VPA treatment 
was marked, while Rad51 expression in combination 
treated cells was diffuse and unspecific. Together these 
results suggest that the capacity of HU to induce DNA 
DSBs is vastly enhanced by the presence of VPA, likely 
due to aberrant expression and localization of Rad51.
Cell death studies confirm synergistic capacity of HU 
and VPA in OCI-AML3 and primary AML blasts
Prior to performing preclinical studies in vivo, we 
wished to corroborate the capacity of HU and VPA to 
synergistically induce cell death in OCI-AML3 cells and 
primary AML blasts whilst remaining non-toxic in healthy 
peripheral blood mononuclear cells. Flow cytometry 
assessment of Annexin-PI expression was performed 
to determine induction of cell death. Dose response 
curves and combination index analysis in OCI- AML3 
cells supported the Hoechst 33342 data presented in 
Figure 1C (Figure 5A + 5B). Primary AML cells from 
10 randomly selected AML patients exhibited a range of 
sensitivity to HU (75 µM) and VPA (0.75 mM) alone or in 
combination when treated for 24 hrs (Figure 5C, Table 1). 
Combining the results from all ten patients demonstrated a 
significant reduction in mean viability for the HU and VPA 
combination treatment against either compound alone 
(Figure 5C). Furthermore, synergism, as calculated by 
Bliss Independence, was obtained in 9 of the 10 patients 
samples assessed (Figure 5D). The viability of PBMCs 
from 4 healthy donors exposed to the HU or VPA alone or 
in combination for 72 hrs was determined by Annexin- PI 
staining to reveal no significant increase in cell death 
(Figure 5E).
The combination of HU and VPA significantly 
inhibits disease progression in human xenograft 
models of AML
To evaluate the capacity of combination therapy 
in vivo, the compounds were evaluated in both an OCI-
AML3-derived orthotopic model of AML and a primary 
patient-derived AML xenograft (PDX) (Figure 6). In 
both models AML cells were engrafted into NOD/
SCID IL2rγnull (NSG) mice. The dosing regime for 
monotherapies and combination treatment was identical 
in both experiments, though the treatment initiation date 
differed to reflect differing disease burdens. Preliminary 
toxicity studies indicated the dosing regime to be well 
tolerated with minimal adverse effects (Supplementary 
Figure 2A). The survival curve of the OCI-AML3 
orthotropic model illustrates clearly that single agent 
treatments provoked limited disease response preclinically. 
Remarkably, a significant increase in survival was 
observed in combination treated animals compared 
with controls (p = 0.0003), VPA (p = 0.0001) and HU 
(p = 0.0014) treated animals (Figure 6A). In a second 
in vivo experiment using an aggressive primary AML PDX 
model, optical imaging with fluorescently conjugated, 
multiplexed monoclonal antibodies targeting human 
leukaemia cells was employed [31, 32]. The purpose of 
this study was to visualise and quantify the efficacy of the 
combination in vivo. To facilitate imaging therapy was 
initiated in the stages of advanced disease [31]. In vitro 
studies performed on the primary AML cells used to 
generate the PDX model confirmed the superiority of the 
combination compared with monotherapies (Figure 6B). 
Disease progression before (Day 21) and after (Day 28) 
treatment was monitored using optical imaging providing 
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a powerful insight into the therapeutic impact of the 
treatments employed. Combination therapy significantly 
reduced the total fluorescence of pooled animals at day 28 
compared to both monotherapies (vs. HU p = 0.0005, vs. 
VPA p = 0.0002) and controls (p = < 0.0001), (Figure  5D 
and 5E). Combination of HU and VPA at the doses and 
schedules employed did not adversely affect the body 
weights or condition in either study (data not shown). 
Furthermore, despite being treated during advanced stage 
disease, mice treated with the combination typically 
survived longer compared with monotherapies and control 
animals, though this observation was not statistically 
significant (Supplementary Figure 3A). These data suggest 
that the combination of HU and VPA can impact upon 
aggressive AML models of late stage palliative AML 
therapy. Finally, Figure 6F provides a schematic overview 
of the mechanism described in the article illustrating the 
molecular insults attributed to HU and VPA, and how the 
wt expression of p53 ultimately determines cell death or 
survival in AML cells.
DISCUSSION
Enhanced efficacy with combination therapy 
was observed to varying degrees in four AML cell 
lines (MV4– 11, OCI-AML3, MOLM-13, HL-60) 
compared with single agent treatment (Figure 1). At 
clinically relevant doses the mutational status of the p53 
protein significantly influenced combination efficacy 
(Figure 1E–1G). The primary AML cells examined 
were predominantly p53 wild-type and therefore should 
reflect the general AML patient population (Table 1). The 
tendency of enhanced combination effect was recapitulated 
in these samples (Figure 5) but the relatively limited 
efficacy observed in some wild-type p53 patient cells 
(I and H) suggests that other factors may also influence 
therapy response. When comparing MOLM-13 shp53 and 
MOLM-13 wt p53 cells combination efficacy proved to 
be significantly more efficient in those cells containing 
wt p53. Whilst approximately 90% of AML patients are 
deemed p53 wild-type, a recent study suggests that some 
Figure 3: Complimentary regulation of cell cycle status following combination therapy in OCI-AML3 cells. 
(A) OCI- AML3 cells were treated with HU (100 µM), VPA (1 mM) and the combination of both for 24 hrs before cells were stained with 
PI and cell cycle status analysed by flow cytometry. Analyses was performed in 3 independent experiments with Figure (A) providing 
representative plots. (B) Comparison of OCI-AML3 cell populations defined as S-phase or Sub G1 (necrotic) at 24 hrs, 48 hrs and 72 hrs 
combination treatment with HU (100 µM) and VPA (1 mM). N = 3. (C) OCI-AML3 cells were incubated for 24 hrs with doses of HU 
(100 µM and 150 µM) and VPA (1 mM and 1.5 mM). Immunoblotting was with antibodies towards p21 and actin. (D) OCI-AML3 cells 
were treated with HU (100 µM), VPA (1 mM) and the combination of both for 72 hrs. Combination experiments were performed where 
monotherapies where added for the first 24 hrs with the secondary treatment added for the final 48 hrs of the experiment (Pretreatment 
with HU/VPA). Apoptosis was determined by Annexin-PI. N = 3. The two alternate sequence studies proved to significantly affect the 
compounds capacity to induce apoptosis (**P < 0.01).
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of these patients may harbour residual p53 mutant clones 
that are infrequent and typically undetected [28]. This 
suggests that in the context of chemotherapeutic regimes, 
low abundance mutated p53 clones may be selected for 
expansion. To examine whether the HU and VPA share 
this therapeutic limitation we performed a treatment 
recovery assay in MOLM-13 shp53, MOLM-13 wt p53, 
HL-60 and OCI-AML3 cells (Figure 2). Importantly, wt 
p53 was revealed to be critical for mitigating cell cycle 
recovery following combination induced arrest. 
It is recognized that HU specifically targets 
cells during DNA synthesis by depleting the available 
nucleotide pool [14, 33]. Following 24 hrs of combination 
treatment cell cycle analysis showed that OCI-AML3 
cells were predominantly found in S-phase and therefore 
vulnerable from potential genotoxicity incited by HU 
(Figure 3A). In addition we assessed p21 expression 
during drug exposure. It is reported previously that HU 
induced down-regulation of p21 may be required for 
combination driven cell death. Our results confirmed 
Figure 4: Mechanistic studies demonstrate the combinations capacity to regulate DNA damage repair proteins. 
(A) OCI-AML3 cells were treated with HU (100 µM), VPA (1 mM) and the combination of both for 24 and 48 hrs. Immunoblotting was 
performed using antibodies towards γH2AX, p53, Chk1, Rad51 and actin. N = 3. (B) OCI-AML3 cells were treated with HU (100 µM), 
VPA (1 mM) and the combination of both for 24 hrs. Assesment of H2AX and γH2AX expression was performed using flow cytometry with 
the Muse™ H2A.X Activation Dual Detection Kit. N = 3. (C + D) OCI-AML3 cells were treated for 48 hrs with HU (100 µM), VPA (1 mM) 
or in combination, before cytospun, fixed and immunostained for Rad51. Representative image of three independent experiments is shown.
Oncotarget8112www.impactjournals.com/oncotarget
the reduced p21 expression in the presence of HU and 
illustrated that VPA substantially slows passage through 
S-phase in combination treated cells. By altering the 
sequence of drug exposure (delaying addition of HU by 
24 hours) cells were prevented from entry to S-phase and 
protected from apoptosis. Together these observations 
highlighted the importance of the cooperative cell cycle 
arrest previously attributed to these compounds [23]. 
They also suggest that when operating synergistically, the 
compounds depended predominantly on HU driven DNA 
damage to provoke cell death.
The effects of VPA on leukemic cells are diverse 
and pleiotropic [34]. The capacity to influence various 
cellular processes whilst maintaining low toxicity may 
partly explain its amenity to combination strategies. 
Previous studies have implicated HDAC inhibitors in the 
dysregulation of homologous recombination repair (HRR) 
[35, 36]. Our study confirms this property is operative in 
VPA treated AML cells. In combination treatment, where 
cells had incurred substantial DNA DSBs, Rad51 staining 
appeared reduced, diffuse and absent of the characteristic 
nuclear foci. Rad51 nuclear foci are associated with 
the proteins functional role in the repair of DSBs and 
their presence is considered a valid estimation of HRR 
capacity [37, 38]. Interestingly, increased expression of 
Rad51 has been suggested as a mechanism of chemo-
resistance in FLT3 mutated AML [37]. HU induced DSBs 
increase corresponding to dose and drug incubation time 
[39]. At low concentrations or reduced exposure times, 
cellular capacity to recover from stalled replication 
forks is sufficient to avoid incitement of DSBs. This is 
conveyed by the absence of γH2AX expression flowing 
24 hrs treatment with HU, but the subsequent increase at 
48 hrs (Figure 4A–4B). However, the dramatic increase 
of combination-induced γH2AX compared to control 
and mono-treatments exemplifies the capacity for VPA to 
enhance the potency of HU.
In vivo efficacy of the drug combination was 
assessed in two aggressive mouse models of AML 
(Figure 6) [31, 32]. These studies provided key preclinical 
indication that repurposing of these compounds as a low-
toxic combination therapy may have clinical value in 
AML. Our second model assessed combination therapy 
in a patient derived xenograft (PDX) model of AML. 
Multiplexing of fluorescently conjugated monoclonal 
antibodies enabled precise imaging of disease progression 
before and after therapy. We observed no adverse effects 
in either model upon treatment with the combination of 
VPA and HU (Supplementary Figure 2A). Treatment of 
the PDX animals occurred during advanced disease to 
facilitate imaging thus potentially inhibiting therapeutic 
efficacy in regards to survival (Supplementary Figure 3A). 
Nevertheless, in vivo imaging provided a clear indication 
that both the leukemic burden and dissemination of 
AML blasts was significantly reduced in mice receiving 
combination therapy when compared to control and mono-
therapy groups. 
We observed difference in efficiency of HU and 
VPA in cell line models and a varying effect in the 
primary AML cells tested in vitro, underscoring the future 
possibility to identify responders or non-responders 
of HU and VPA based on molecular and biological 
characteristics of the AML disease. Several case reports 
[21] together with our animal models have suggested 
the compounds are unlikely to result in toxicity when 
administered in combination, indicating the feasibility 
Table 1: Clinical and biological characteristics of the 11 AML patients included in the study
Gender Age Previous FAB CD34 Cytogenetics FLT3 NPM-1 P53 Synergy Ranking Patient ID
M 32 De novo M3 Positive t(15;17) ITD wt wt 1 G
F 87 De novo M0 Positive Del 5 (q13, q33) Normal nt wt 2 D
M 78 De novo M4 Negative +8 Nt nt wt 3 C
F 29 De novo M5 Positive Normal ITD+Asp835 wt wt 4 F
M 76 MDS  nt Positive Normal nt nt nt 5 B
M 82 De novo  nt Positive +8 wt wt wt 6 A
F 78 De novo M1 Negative Normal ITD Ins wt 7 E
F 18 De novo M4 Positive Inv16 wt wt wt 8 I
M 64 De novo M5 Negative Normal wt Ins nt 9 H
M 76 MDS  nt Positive Normal nt nt wt 10 J
F 59 De novo M4 Positive Normal ITD Ins wt nt PDX 
FAB, French-American-British; F, Female; FLT3, FMS-like tyrosine kinase-3; Ins, Insertion; ITD, Internal tandem duplicate; 
M, Male; MDS, Myelodysplastic syndrome; NPM1, Nucleophosmin-1; nt, Not tested; PDX, Refers to patient cells used to 
generate patient derived xenograft model implemented in Figures 6B and 6C; wt, wild type. Synergy ranking determined 
by the difference in actual vs. expected viability values using bliss independence analysis, 1 = strongest, 10 = weakest 
(Figure 5D). Patient IDs are chosen arbitrarily for reference to Figure 5C.
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Figure 5: Annexin-PI studies demonstrate synergy in OCI-AML3, primary AML blasts and the non-toxic effect of the 
combination in PBMCs. (A) OCI-AML3 cells were treated with increasing doses of HU (0–200 µM) and VPA (0–2 mM) alone or in 
combination at a fixed ratio (1:10) for 72 hrs and apoptosis was determined by Annexin-PI to generate dose response curves. N = 3. (B) The 
data generated in figure (A) enabled CI vales to be plotted at fa (0–1.0). (C) Differences in means of viability between HU (75 µM), VPA 
(0.75 mM) and combination of both for 24 hrs for the pooled patient data analyzed by Annexin-PI. Results are given as means ± s.e. of mean 
(**P < 0.01, n = 10). (D) Bliss Independence analysis of expected and actual response for the combinational therapy of HU (75 µM) and 
VPA (0.75 mM) for each of the individual AML patient samples analyzed by Annexin-PI. (E) Peripheral blood mononucleocytes (PBMCs) 
obtained from four healthy donors were treated with HU (100 µM), VPA (1 mM) and the combination of both for 72 hrs and apoptosis was 
determined by Annexin-PI. Reduction of viability by the combinational treatment was compared with untreated control cells to reveal a 
non-significant (NS).
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to test HU and VPA in a controlled clinical trial of unfit 
elderly AML patients. We believe that repositioning of 
HU and VPA as a combination therapy could significantly 
enhance the palliative care of patients unsuited to intensive 
chemotherapy, particularly if non-responders can be 
predicted prior to initiation of treatment
Figure 6: Combinational therapy of HU and VPA represses AML in vivo. (A) Survival data presented in Kaplan-Meyer curve 
illustrating the efficacy of HU and VPA and increased survival of combination therapy (log-rank P = 0.0003 vs controls, P = 0.0014 vs 
HU, P = 0.0001 vs VPA) in the OCI-AML3 orthotopic model of AML. Arrows indicate days on which animals were dosed with both 
compounds. Control (n = 8), HU (n = 8), VPA (n = 8) and combination (n = 7). (B) Primary AML cells from the same generation used to 
generate the PDX model were thawed and treated with HU (75 µM), VPA (0,75 mM) and the combination of both for 24 h and apoptosis 
determined by Annexin-PI staining. (C + D) Imaging with multiplexed mAbs was performed before initiation of therapy (day 21) and 1 
week later (day 28). Control (n = 8), HU (n = 8), VPA (n = 8) and combination (n = 6). Representative images of mice after treatment reveal 
a significant reduction in total fluorescence (photon count per second) of combination treated mice compared with vehicle controls and 
monotherapies. Combination compared with control (p < 0.0001), VPA (p = 0.0002) and HU (p = 0.0005). (E) Schematic overview of the 
combination mechanism of action and key molecular events determining cell death or survival in AML cells exposed to HU and VPA. HU, 
Hydroxyurea; VPA, Valproic Acid; DSB, Double strand breaks; HR, homologous recombination.
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MATERIALS AND METHODS
Cell lines, primary AML cells and healthy 
PBMCs
Seven leukemic cell lines were included in the 
study, OCI-AML3 (DSMZ), MV4–11, HL-60, KG1-A, 
THP-1, K562 and MOLM-13 (ATCC). p53 knocked 
down MOLM-13 cells and empty vector (MOLM-13 
shp53) were generated by retroviral transfection for stable 
expression of shRNA against p53 using the pRETRO 
SUPER-p53 vector [5]. The concentration of puromycin 
was steadily increased to 400 µg/ml over a two-week 
period. Primary AML cells were acquired from patients 
at Haukeland University Hospital following informed 
consent. Approval was obtained from the regional Ethics 
Committee (REK Vest; http://helseforskning.etikkom.
no; Norwegian Ministry of Education and Research). 
Normal peripheral blood lymphocytes were obtained from 
healthy blood donors (Blood bank, Haukeland University 
Hospital, Bergen, Norway).
Cell death assays
Evaluation of cell death and apoptosis in cell lines 
and primary AML cells after drug treatment was performed 
using Hoechst 33342 staining of nuclear morphology and 
AnnexinV-propidium idodide (Annexin- PI) detection 
of apoptosis by flow cytometric analysis. Assays were 
performed as previously described [5].
Western blotting 
Western Blotting was performed as previously 
described [5]. The following antibodies were used; Actin 
(sc- 4778) Chk1 (DCS-310) p53 (Bp53–12), Rad51 (sc-8349) 
(all from Santa Cruz Biotech), p21 (EA10, Abcam,), γH2AX 
(DR1017) and H2AX (DR1016) (both from CalBiochem, 
Germany). Goat-POD- anti-mouse or anti-rabbit antibody 
secondary antibodies (Jackson ImmunoResearch) were used 
as appropriate for primary antibody detection.
Immunofluorescence
Following treatment incubations cells were cytospun 
onto coverslips followed by fixation and permeabilization 
with 4% paraformaldehyde for 20 min and ice-cold 99% 
methanol for at least 20 min at -20 degrees or stored, 
respectively. Cells were then blocked with 0.5 % Bovine 
Serum Albumin (BSA) (Roche Diagnostics GmbH) 
in 1XPBS for 15 min before incubation with primary 
antibody, rabbit Rad51 (1:200, sc-8349), γH2AX (DR1017, 
CalBiochem, Germany) or Nsb-1 (D6J5I, Cell Signalling 
Technology) diluted in 1XPBS with 0.5% BSA at 4°C over 
night. After three washes in 1XPBS, cells were incubated 
with secondary antibody (1:5,000 of Alexa 568 goat anti-
rabbit (Invitrogen Molecular Probes)) diluted in 1XPBS with 
0.5% BSA, was performed in the dark for 1 hour at room 
temperature. Finally, the coverslip was washed three times 
with 1XPBS, dipped once in water and mounted in 5 μl 
Fluoro-gel II with DAPI (Electron Microscopy Sciences, PA, 
USA). Images of were acquired with a Zeiss Axio Observer 
Z1 inverted microscope (Carl Zeiss Microimaging GmbH, 
Germany) and analyzed by the AxioVision 4.8.2 software.
Cell cycle analysis
Cells were fixed in 70% ethanol in PBS overnight. 
For DNA content analysis cells were pelleted and 
resuspended in PBS containing 1 mg/ml RNase (Sigma 
Aldrich) and 10 mg/ml PI, incubated at room temperature 
for 30 min, then analysed using the Accuri C6 flow 
cytometer (BD Sciences).
H2AX and γH2AX expression assay
The assessment of H2AX expression in OCI-AML3 
cells was performed using the H2AX Muse™ H2A.X 
Activation Dual Detection Kit (Millipore). 1 × 105 cells 
were analyzed from each sample condition following 
48 hrs drug exposure. Samples were prepared in strict 
accordance to the manufacturer’s procedure and run on 
the Muse® Cell Analyzer flow cytometer.
Monoclonal antibody conjugation
Monoclonal antibodies (mAbs) CD45 (clone F10–
89–4), CD33 (clone WM53), HLA ABC (clone W6/32; all 
AbD Serotec) were conjugated to Alexa Fluor 680 using 
the SAIVI Alexa Fluor 680 Labelling Kit (Invitrogen) 
as described [32]. Protein concentrations of the Alexa 
Fluor 680–conjugated mAbs degree of labelling were 
determined using a Nanodrop 1000 spectrophotometer 
(Thermo Fischer Scientific).
Optical imaging
Prior to imaging, mice were depilated and 
anesthetized with 1–2% isoflurane (Isoba; Schering-
Plough), 0.2 L/min of O2, and 0.2 L/min of N2. NIR images 
were obtained with the eXplore Optix or Optix MX3 Small 
Animal Molecular Imager system (ART Inc). NIR imaging 
scans (λex = 670 nm, λem = 700 LP, laser repetition rate 
80 MHz, raster scan points 1 mm apart) were obtained 
24 hours after administration of Alexa Fluor 680–labelled 
mAbs (total mAb concentration of 1 µg/g). Optiview 
software (Versions 1.04 and 2.02; ART Inc) was use to 
analyse images and perform fluorescence lifetime gating. 
Mouse xenograft models
All animal experiments were approved by the 
Norwegian Animal Research Authority and performed 
in accordance with The European Convention for the 
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Protection of Vertebrates Used for Scientific Purposes. 
Intravenous injection of OCI-AML3 cells (1.5 × 106 
cells/100 μL/mouse) and primary AML cells (5 × 106 
cells/100 μL/mouse) was performed on female NOD/SCID 
IL2rγnull (NSG) mice (Vivarium, University of Bergen; 
originally a generous gift of Dr Leonard D. Shultz, The 
Jackson Laboratory). 
Dosing regime
VPA (100 mg/mL, Orfiril) was sterile filtered from 
the vial. HU (76.05 g/mol, Sigma
Aldrich) was daily prepared with saline to a 
concentration of 200 mg/mL.
In both xenograft experiments mice were treated for 
five consecutive days. In the primary AML model therapy 
was initiated day 21, whilst in the OCI-AML3 models 
treatment began day 14. Animals were divided into four 
groups, control animals receiving 50 µl sterile saline, VPA 
350 mg/kg/day, HU 500 mg/kg/day, and combination 
(VPA 350 mg/kg/day + HU 500 mg/kg/day). All groups 
contained a minimum of 5 animals and all dosing was 
performed by intraperitoneal injection.
Statistical analysis
In cell death assays results are displayed as the mean 
+/− standard deviation. Synergism was calculated by the 
Chou-Talalay method [40] or by Bliss Independence analysis 
[41]. In both in vitro and in vivo studies statistical significance 
between the averages of varying treatment groups were 
determined using a two-tailed Student t test. In vivo survival 
data was evaluated using the Kaplan and Meier analysis 
method. A one-way analysis of variance (ANOVA) was 
performed to ensure no statistical significant difference in 
weights between the animals in the treatment groups.
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